Patents by Inventor Guo-Liang Yu
Guo-Liang Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090221008Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: March 30, 2007Publication date: September 3, 2009Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich, Marc Chevrier
-
Patent number: 7575896Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: GrantFiled: November 8, 2007Date of Patent: August 18, 2009Assignee: Epitomics, Inc.Inventor: Guo-Liang Yu
-
Publication number: 20090169565Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: ApplicationFiled: February 26, 2009Publication date: July 2, 2009Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen
-
Publication number: 20090155824Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: ApplicationFiled: October 31, 2008Publication date: June 18, 2009Inventors: FERNANDO JOSE REBELO DO COUTO, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Patent number: 7534428Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides and antibodies that bind TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: May 3, 2006Date of Patent: May 19, 2009Assignee: Human Genome Sciences, Inc.Inventors: Reiner L. Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
-
Publication number: 20090104189Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: September 12, 2008Publication date: April 23, 2009Applicant: Human Genome Sciences, Inc.Inventors: GUO-LIANG YU, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich
-
Patent number: 7514081Abstract: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.Type: GrantFiled: June 30, 2006Date of Patent: April 7, 2009Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen
-
Publication number: 20090068201Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: ApplicationFiled: July 9, 2008Publication date: March 12, 2009Applicant: Human Genome Sciences, Inc.Inventors: GUO-LIANG YU, Reinhard Ebner, Jian Ni, Craig A. Rosen
-
Publication number: 20090062510Abstract: Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.Type: ApplicationFiled: April 19, 2007Publication date: March 5, 2009Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Pedro Alfonso, Reiner L. Gentz, Jeffrey Y. Su
-
Publication number: 20090011983Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: May 8, 2007Publication date: January 8, 2009Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Daniel R. Soppet, Kenneth C. Carter, Daniel P. Bednarik, Gregory A. Endress, Guo-Liang Yu, Jian Ni, Ping Feng, Paul E. Young, John M. Greene, Ann M. Ferrie, D. Roxanne Duan, Jing-Shan Hu, Kimberly A. Florence, Henrik S. Olsen, Carrie L. Fischer, Reinhard Ebner, Laurie A. Brewer, Paul A. Moore, Yanggu Shi, David W. LaFleur, Yi Li, Zhizhen Zeng, Hla Kyaw
-
Publication number: 20090005301Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: June 7, 2007Publication date: January 1, 2009Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Reinhard Ebner, David W. LaFleur, Paul A. Moore, Henrik S. Olsen, Craig A. Rosen, Steven M. Ruben, Daniel R. Soppet, Paul E. Young, Yanggu Shi, Kimberly A. Florence, Ying-Fei Wei, Charles Florence, Jing-Shan Hu, Yi Li, Hla Kyaw, Carrie L. Fischer, Ann M. Ferrie, Ping Fan, Ping Feng, Gregory A. Endress, Patrick J. Dillon, Kenneth C. Carter, Laurie A. Brewer, Guo-Liang Yu, Zhizhen Zeng, John M. Greene
-
Patent number: 7462697Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: GrantFiled: November 8, 2004Date of Patent: December 9, 2008Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin B. Hendricks, S. Ellen Wallace, Guo-Liang Yu
-
Publication number: 20080248046Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and/or antagonists of DR5 activity.Type: ApplicationFiled: January 18, 2008Publication date: October 9, 2008Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
-
Publication number: 20080220431Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: ApplicationFiled: November 8, 2007Publication date: September 11, 2008Inventor: Guo-Liang Yu
-
Patent number: 7402409Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: GrantFiled: January 23, 2003Date of Patent: July 22, 2008Assignee: Epitomics, Inc.Inventor: Guo-Liang Yu
-
Publication number: 20080171016Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.Type: ApplicationFiled: March 11, 2008Publication date: July 17, 2008Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
-
Patent number: 7393943Abstract: Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.Type: GrantFiled: December 6, 1996Date of Patent: July 1, 2008Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Pedro Alfonso, Reiner Gentz, Jeffrey Y. Su
-
Publication number: 20080096821Abstract: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: ApplicationFiled: December 12, 2007Publication date: April 24, 2008Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner Gentz
-
Patent number: 7357927Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.Type: GrantFiled: July 5, 2002Date of Patent: April 15, 2008Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
-
Publication number: 20080085835Abstract: Disclosed is substantially pure DNA encoding an Arabidopsis thaliana Rps2 polypeptide, substantially pure Rps2 polyneptide; and methods of using such DNA to express the Rps2 polypeptide in plant cells and whole plants to provide, in transgenic plants, disease resistance to pathogens. Also disclosed are conserved regions characteristic of the RPS family and primers and probes for the identification and isolation of additional RPS disease-resistance genes.Type: ApplicationFiled: September 29, 2006Publication date: April 10, 2008Inventors: Frederick M. AUSUBEL, Brian J. Staskawicz, Andrew F. Bent, Douglas Dahlbeck, Fumiaki Katagiri, Barbara N. Kunkel, Michael Nicholas, Guo-Liang Yu, Barbara Baker, Jeffrey Ellis, John Salmeron